Loading...
*  Cytarabine
MedlinePlus page on cytarabine ADAP drugs page on cytarabine BC Cancer network page on cytarabine Chembank entry Pharmacy and ... Cytarabine-5´-triphosphate is a substrate for SAMDH1. Furthermore, SAMHD1 has been shown to limit the efficacy of cytarabine ... Cytarabine is able to inhibit herpesvirus and vaccinia virus replication in cells during tissue culture. However, cytarabine ... Cytarabine is rapidly deaminated by cytidine deaminase in the serum into the inactive uracil derivative. Cytarabine-5´- ...
*  SAMHD1
... has been shown to be a biomarker and influence arabinose C (ara-C; cytarabine) responsiveness. Viral protein x (Vpx) has ... February 2017). "SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia". Nature ... February 2017). "Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies". Nature ... been proposed to be potential therapy to improve cytarabine therapy for hematological malignancies. GRCh38: Ensembl release 89 ...
*  Learning problems in childhood cancer
... high-dose methotrexate or cytarabine; or intrathecal chemotherapy). As the mortality rates of childhood cancers have plummeted ...
*  DAT (chemotherapy)
... cytarabine) - an antimetabolite; (T)hioguanine - another antimetabolite. Randomized Comparison of DAT Versus ADE as Induction ...
*  Chemotherapy-induced acral erythema
ISBN 0-7216-2921-0. Palmar-plantar rash with cytarabine therapy. Rosenbeck L, Kiel PJ. N Engl J Med. 2011 Jan 20;364(3):e5. ... cytarabine, doxorubicin, and fluorouracil and its prodrug capecitabine. Targeted cancer therapies, especially the tyrosine ...
*  DAM (chemotherapy)
... cytarabine) - an antimetabolite; (M)ercaptopurine - another antimetabolite.. ...
*  Hyper-CVAD
Course B consists of methotrexate and cytarabine. The protocol was originally developed to treat leukemia in young, fit ... is an Immunosuppressant 40 mg/day IV or PO Days 1-4 and 11-14 Cytarabine or Ara-C (Cytosar) is an antimetabolite 70 mg IT Day 7 ...
*  Arabinofuranosylcytosine triphosphate
It is the biologically active form of cytarabine. Ara-CTP - Compound Summary, PubChem.. ...
*  Flucytosine
The cytostatic cytarabine inhibits the antimycotic activity of flucytosine. Symptoms and their severities are unknown, because ...
*  Equilibrative nucleoside transporter 1
2002). "Potential mechanisms of resistance to cytarabine in AML patients". Leuk. Res. 26 (7): 621-9. doi:10.1016/S0145-2126(01) ...
*  ADE (chemotherapy)
ADE regimen consists of three drugs: Ara-C (cytarabine) - an antimetabolite; Daunorubicin - an anthracycline antibiotic that is ...
*  Acute erythroid leukemia
It consists of chemotherapy, frequently consisting of cytarabine, daunorubicin, and idarubicin. It can also involve bone marrow ...
*  R-HDAC
It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine. High-dose Ara-C (HDAC) without rituximab ... Nordic Protocol (Maxi-CHOP and High Dose Cytarabine) for Mantle Cell Lymphoma (MCL). ...
*  Neoplastic meningitis
The most common chemicals used are liposomal cytarabine (DepoCyte) and intrathecal methotrexate (MTX). In combination, ... Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurological Sciences ... intrathecal chemotherapy most often comprises methotrexate, cytarabine, thiotepa and steroids. Ventriculoperitoneal shunts may ...
*  Neutrophilic eccrine hidradenitis
NEH was first described in 1982 in a patient with acute myeloid leukaemia (AML) who had received cytarabine as chemotherapy. ... Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. Flynn TC, Harrist ... These include: Bleomycin, chlorambucil, cyclophosphamide, cytarabine, doxorubicin, lomustine, mitoxantrone, topotecan, and ...
*  Adult neurogenesis
Other cell division inhibitors commonly used in studies are cytarabine and temozolomide. Another method used to study the ...
*  Vorinostat
"Zolinza, Idarubicin, Cytarabine Combination Yields High Response Rates In MDS Patients (ASH 2011)". Clinical trial number ... has given encouraging results in a phase II trial for myelodysplastic syndromes in combination with idarubicin and cytarabine. ...
*  Acute myeloid leukemia
All FAB subtypes except M3 are usually given induction chemotherapy with cytarabine (ara-C) and an anthracycline (most often ... Other alternative induction regimens, including high-dose cytarabine alone, FLAG-like regimens or investigational agents, may ... "A randomized study of high-dose cytarabine in induction in acute myeloid leukemia". Blood. 87 (5): 1710-7. PMID 8634416. Huang ... daunorubicin). This induction chemotherapy regimen is known as "7+3" (or "3+7"), because the cytarabine is given as a ...
*  Chemotherapy
The deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, ...
*  Lestaurtinib
"Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". ...
*  History of cancer chemotherapy
March 2003). "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid ...
*  Oncology
Acute myeloid leukemia (AML) Induction with chemotherapy (Daunorubicin + Cytarabine) followed by consolidation chemotherapy ( ... High dose cytarabine). Stem cell transplantation for high-risk patients. Chronic lymphocytic leukemia (CLL): Chemo- ...
*  Deoxycytidine kinase
"Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells". ...
*  Fractional kill
Cytarabine, a DNA-synthesis inhibitor also known as ara-C, is cited as the classic cell cycle phase-specific agent. ... In fact, a trace through the literature on the S-phase specificity of cytarabine leads to studies that simply assume S-phase ... Chemotherapy dosing schedules have been optimized based on the fact that cytarabine is only expected to be effective in the DNA ... Consistent with this, leukemia patients respond better to cytarabine treatments given every 12 hours rather than every 24 hours ...